Mycobacterium tuberculosis ClpP1 and ClpP2 Function Together in Protein Degradation and are Required for Viability in vitro and During Infection

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Raju, Ravikiran M., Meera Unnikrishnan, Daniel H. F. Rubin, Vidhya Krishnamoorthy, Olga Kandror, Tatos N. Akopian, Alfred L. Goldberg, and Eric J. Rubin. 2012. Mycobacterium tuberculosis ClpP1 and ClpP2 function together in protein degradation and are required for viability in vitro and during infection. PLoS Pathogens 8(2): e1002511.

Published Version
doi:10.1371/journal.ppat.1002511

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:9368031

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
**Mycobacterium tuberculosis** ClpP1 and ClpP2 Function Together in Protein Degradation and Are Required for Viability *in vitro* and During Infection

Ravikiran M. Raju1,*, Meera Unnikrishnan1,*, Daniel H. F. Rubin1, Vidhya Krishnamoorthy1, Olga Kandror2, Tatos N. Akopian2, Alfred L. Goldberg2, Eric J. Rubin1*

1 Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, United States of America. 2 Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, United States of America

**Abstract**

In most bacteria, Clp protease is a conserved, non-essential serine protease that regulates the response to various stresses. Mycobacteria, including *Mycobacterium tuberculosis* (Mtb) and *Mycobacterium smegmatis*, unlike most well studied prokaryotes, encode two ClpP homologs, ClpP1 and ClpP2, in a single operon. Here we demonstrate that the two proteins form a mixed complex (ClpP1P2) in mycobacteria. Using two different approaches, promoter replacement, and a novel screen for essential genes in Mtb predicted that ClpP2 and the ATPase adapters ClpC1 and ClpX, were required for normal growth specifically in the presence of antibiotics that increase errors in translation. We further show that the ClpP1P2 protease is required for the degradation of proteins tagged with the SsrA motif, a tag co-translationally added to incompete peptide products. Using active site mutants of ClpP1 and ClpP2, we show that the activity of each subunit is required for proteolysis, for normal growth of Mtb *in vitro* and during infection of mice. These observations suggest that the Clp protease plays an unusual and essential role in Mtb and may serve as an ideal target for antimycobacterial therapy.

**Introduction**

Intracellular protein degradation is critical for maintaining cellular homeostasis through protein quality control and regulation of numerous biological pathways [1,2]. In eukaryotes, the ubiquitin-proteasome pathway constitutes the predominant degradation pathway [3]. Most prokaryotes, however, possess a variety of ATP-dependent serine protease complexes, such as Lon and Clp protease [4], and some actinomycetes and archaea contain proteasomes, which are threonine proteases. Interestingly, *Mycobacterium tuberculosis* (Mtb) encodes both a proteasome and Clp protease. While recent work has explored the role of the Mtb proteasome [5–7], little is known about mycobacterial Clp protease. This serine protease was first discovered and is best characterized in *Escherichia coli* [8,9]. The Clp proteolytic complex is formed by the association of proteolytic subunits, ClpP, with ATPase adapters, ClpX or ClpA in Gram-negative organisms and ClpX or ClpC in Gram-positive organisms. *E. coli* ClpP is a tetradecamer composed of two stacked heptameric rings of identical ClpP subunits that form an internal proteolytic chamber [10]. This core associates with distinct hexameric ATPase adapters, ClpX and ClpC1 in mycobacteria, which provide substrate specificity and catalyze ATP-dependent unfolding of globular proteins [11,12]. In *E. coli*, the ClpXP protease is involved in the regulation of the DNA damage response and degradation of SsrA-tagged peptides stalled on the ribosome [13,14]. Clp proteolytic enzymes are also required for full virulence in several pathogenic organisms, including *Listeria monocytogenes* where the protease is required for the production of *α*-listeriolysin [15,16]. In most bacteria including *E. coli*, Clp protease is dispensable for normal growth, and in fact, until recently, the only organism in which *clpP* has been found to be essential is *Caulobacter crescentus*, where Clp degrades CtrA, an inhibitor of cell cycle progression [17].

Unlike most bacteria, which have a single ClpP subunit, the genome of Mtb encodes two closely related ClpP homologs, *clpP1* and *clpP2*, in a single operon. A transposon-based mutagenesis screen for essential genes in Mtb predicted that ClpP2 and the ATPase adapters ClpC1 and ClpX, were required for normal growth [18] while a recent publication has shown that ClpP1 is essential [19]. Here, we show that both ClpP1 and ClpP2 are required for growth, and that their activity is important for the removal of abnormal proteins. Our data suggest that ClpP1 and ClpP2 assemble to form a single proteolytic complex, referred to as...
Importance of Clp Protease in Mycobacteria

Author Summary

Due to the significant and rapid rise in multidrug resistant *Mycobacterium tuberculosis* (Mtb), there is an urgent need to validate novel drug targets for the treatment of tuberculosis. Here, we show that Clp protease is an ideal potential target. Mtb encodes two ClpP genes, ClpP1 and ClpP2, which associate together to form a single proteolytic complex, referred to as ClpP1P2. Both proteins are required for growth *in vitro* and in a mouse model of infection. Depletion of either protein results in rapid death of the bacteria. Interestingly, this is rare among bacteria, most of which have only one ClpP gene that is dispensable for normal growth. We also show that Clp protease plays an important quality control role by clearing abnormally produced proteins. As known antimycobacterial therapeutics increase errors in protein synthesis, inhibitors of ClpP1P2 protease in Mtb may prove synergistic with already existing agents.

ClpP1P2, that is required for normal growth *in vitro* and during infection. In related studies, we have found that although pure ClpP1 and ClpP2 by themselves form tetradecamers, they are inactive. However, in the presence of low molecular weight activators they reassociate to form a mixed tetradecamer, ClpP1P2, which is capable of proteolysis (Akopian et. al., manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted). The unusual properties of this heteromeric complex, the absence of such an enzyme in the eukaryotic manuscript submitted).

Results

ClpP1 and ClpP2 subunits interact to form a single proteolytic complex

Mycobacterial genomes contain two homologous ClpP protease genes, clpP1 and clpP2, arranged in a putative operon. To investigate whether the two proteins may function together in a complex, we co-expressed Mtb clpP1 and clpP2, each containing a different C terminal epitope tag, in *Mycobacterium smegmatis* (Msm). We used affinity chromatography with nickel resin to isolate 6×His tagged Mtb ClpP2 together with associated proteins from the Msm cell lysate. As shown in Figure 1A, a fraction of the c-myc tagged ClpP1 bound to the Ni column and co-eluted with ClpP2. To verify that ClpP1 and ClpP2 co-eluted from the Ni column may be associated in a complex, we applied the fraction from the Ni column containing both proteins to an anti-c-myc agarose column and analyzed by SDS PAGE. Figure 1B shows that a large fraction of the ClpP2 was associated with ClpP1. Incidentally, expression of the Mtb proteins in Msm also led to the co-isolation of Msm ClpP1 and ClpP2, as shown by tandem mass spectrometry of the purified complex. In each case, peptides present uniquely in Mtb or Msm ClpP1 and ClpP2 were detected (Figure 1C).

If ClpP1 and ClpP2 do in fact associate to form a single proteolytic core, we reasoned that mutations blocking the catalytic activity of one subunit might reduce that activity of the enzyme. We identified likely active site residues of ClpP1 and ClpP2 by mapping the Mtb proteins onto *E. coli* ClpP and locating the catalytic triad of Asp-His-Ser, which is characteristic of serine proteases. In both cases, the serine likely to be responsible for nucleophilic attack was replaced by an alanine (ClpP1 S98A and ClpP2 S110A). To analyze the effects of these mutations, we expressed and purified 6×His-tagged forms of each protein, and assayed their effect on the enzymatic activity of the wild type ClpP1P2 in an *in vitro* peptidase assay (Akopian et. al., manuscript submitted). Enzyme activity of the reconstituted ClpP1P2 complex was quantified using cleavage of the fluorescence reporter, Z-Gly-Gly-Leu-AMC. As shown in Figure 1D, addition of an excess of mutated ClpP1 or ClpP2 to the active wild type ClpP1P2 complex inhibited proteolytic cleavage of a fluorescent peptide substrate, presumably by replacing the wild type subunits. These results suggest that the ClpP1 and ClpP2 subunits interact to form a single proteolytic complex *in vitro*, that each active site is important for activity, and that these mutations can be used as dominant negative inhibitors.

Both ClpP1 and ClpP2 are required for normal growth *in vitro*

We employed three complementary strategies to determine if ClpP1 and ClpP2 are required for normal growth in mycobacteria. First, using mycobacterial recombineering [20], we replaced the endogenous promoter of clpP1 and clpP2 in Msm with a tetracycline-inducible promoter (Figure 2A, Figure S1). Introduction of a tetracycline repressor resulted in a strain (p tet clpP1P2) that could only be maintained in the presence of the inducer anhydrotetracycline (ATc) (Figure 2B). In the absence of this compound, growth did not occur, but could be restored by the presence of an episomal plasmid containing both clpP1 and clpP2. Plasmids expressing only clpP1 or clpP2 alone could not rescue growth and depletion of either subunit resulted in bacterial death (Figure 2C). Since complementation was conducted with Mtb homologs and subunits from different species associate into a functional tetradecamer, the ClpP1P2 complex is likely very similar in Msm and Mtb. Furthermore, active site mutants of either ClpP1 or ClpP2 were unable to complement p tet clpP1P2 in the absence of ATc, suggesting that the activity of both subunits were required for normal growth (data not shown).

Second, we inserted a tetracycline inducible promoter upstream of the clpP1P2 operon via homologous recombination in Msm creating a strain in which clpP2 was inducibly expressed (Figure 2D), and clpP1 was under the control of its native promoter (p tet clpP2). In accord with the previous findings, the growth of this strain was dramatically inhibited in the absence of ATc (Figure 2E).

Third, we used a system of inducible protein degradation recently developed in Msm (Figure 3A) [21]. Briefly, we employed mycobacterial recombineering to add an inducible degradation (ID) tag to the C-terminus of ClpP2 (clpP2-ID). Upon cleavage of the tag by a tetracycline inducible HIV-2 protease, an SsrA sequence is revealed on the substrate that directs degradation of the protein. By inserting epitope tags C-terminally to the HIV-2 protease recognition motif (FLAG) and N-terminally to the SsrA tag (c-myc), we were able to monitor the amount of ClpP2 by immunoblotting. As shown in Figure 3B, induction of HIV-2 protease resulted in degradation of the majority of ClpP2 and inhibited bacterial growth (Figure 3C). Using this system, we did not observe cell death, perhaps due to incomplete inhibition, as would be expected for a system where the protease targets itself. Loss of ClpP2, as measured by immunoblotting, was rapid and reached near completion within hours. Furthermore, the growth defect was complemented by expression of Mtb clpP2 using a constitutively active promoter. A similar approach with ClpP1 was unsuccessful as extended C-terminal tagging was not tolerated, and the ID tag was indiscriminately cleaved. Collectively, these results confirm that both ClpP1 and ClpP2 are required for
normal growth in mycobacteria, presumably because they function together in the ClpP1P2 complex.

Mycobacterial Clp protease plays a role in protein quality control

In other bacteria, Clp plays a role in degrading abnormal proteins such as SsrA-tagged peptides that stall on the ribosome [22]. To determine the importance of ClpP1P2 protease in the degradation of misfolded proteins, we used antibiotics that alter protein synthesis in distinct ways including chloramphenicol, which blocks protein elongation without increasing mistranslation rates [23], and streptomycin and amikacin, which induce translational errors resulting in missense or prematurely-terminated polypeptides [24]. We found that the strain pteP_ClpP2, in which clpP2 expression is regulated by anhydrotetracycline, grows well in low or high concentrations of ATc, 1 to 100 ng/mL (Figure 4A). Maintenance of low or high concentrations of ATc (Figure 4A, bottom). In contrast, sub-MIC concentrations of the aminoglycosides streptomycin and amikacin significantly inhibited the growth of strains incubated in low concentrations of ATc, while they had no effect on growth of the strain maintained in high concentrations of ATc (Figure 4A, top). Together, these results suggest that ClpP1P2 protease protects against error-prone translation by catalyzing the degradation of misfolded proteins.

To specifically assess whether ClpP1P2 is responsible for the removal of SsrA-tagged peptides in mycobacteria, we fused the mycobacterial SsrA-tag to the C-terminus of GFP (GFP-SsrA) and expressed the construct constitutively on an episomal plasmid. This construct was introduced into the strain clpP2_ID, in which ClpP2 degradation was regulated. In the presence of ClpP2 (and in wild type cells), there was no detectable GFP-SsrA. However, upon depletions of ClpP2 (in wild type cells), there was no detectable GFP-SsrA. However, upon depletion of ClpP2, there was substantial accumulation of GFP-SsrA, as measured by both fluorescence and immunoblot analysis after four hours (Figure 4B, 4C). Quantitative PCR

Figure 1. Mtb ClpP1 and ClpP2 interact, forming a multi-component protease, and share substantial similarity with ClpP1 and ClpP2 homologs in Msm. (A) C-terminally myc-tagged Mtb ClpP1 and 6xHis-tagged Mtb ClpP2 were expressed in Msm. Lysate (lane 1) was prepared and loaded onto a Ni-column. After washing with PBS (lanes 2,3), Ni-bound material was eluted with 50 mM (lane 4), 100 mM (lane 5), and 250 mM (lane 6, 7) of imidazole in PBS, and analyzed by immunoblotting using anti-α-myc and α-6xHis antibodies. (B) Fraction 6 from (A) was applied to an anti-myc column (lane 1). The flow through (lane 2), and bound material (lane 3) were analyzed by immunoblot with α-myc and α-His antibodies. Bound material was released from the anti-myc agarose beads by boiling in Laemmli buffer after washing with PBS. (C) Bands representing ClpP1 and ClpP2 from (B) were sequenced by MS/MS revealing the presence of both Mtb and Msm homologs. Msm specific peptides are indicated by black lines, those specific to Mtb are indicated by red lines. (D) Cleavage of fluorescent peptide Z-Gly-Gly-Leu-AMC was measured in the presence of 1 μg ClpP1, 1 μg Clp2, and the activating peptide Z-Leu-Leu (see accompanying paper). Addition of 5 μg of catalytically inactive mutants of either ClpP1 (ClpP1S) or ClpP2 (ClpP2S) markedly inhibited cleavage by the ClpP1P2 protease. Results graphed are a representative sample of results obtained.
doi:10.1371/journal.ppat.1002511.g001
showed that the rise of GFP-SsrA was not due to transcriptional activation of the gene (Figure S2). GFP lacking the SsrA tag is present at similar levels in all strains (data not shown). Because we cannot detect GFP-SsrA in the presence of Clp activity, we were unable to accurately measure changes in protein stability. However, the rate of accumulation of GFP-SsrA was consistent with the time course of ClpP2 depletion, which occurred over six hours, as shown by immunoblotting. Thus, functional ClpP1P2 protease is vital for the rapid clearance of SsrA-tagged substrates in mycobacteria.

Functional Clp protease is required for growth of Mtb in vitro and during infection

As shown above, catalytically inactive forms of ClpP1 and ClpP2 inhibit proteolysis by the wild type enzyme, possibly by replacement of wild type subunits with inactive ones. To assess whether ClpP1P2 activity is required for the growth of Mtb, we expressed a catalytically inactive form of Mtb clpP1, clpP1 S98A, on a tetracycline-inducible plasmid in wild type Mtb. Addition of ATc led to expression of the catalytically inactive mutant protein and resulted in a significant inhibition of growth (Figure 5A) while overexpression of wild type Mtb clpP1 had no effect.

To determine if the dominant negative mutant of ClpP1 affected ClpP1P2 function during infection, we infected mice with a 3:1 mixture of Mtb expressing clpP1 S98A on a hygromycin-resistant doxycycline inducible plasmid and wild type Mtb (containing a kanamycin-resistant control vector). Mice were fed either normal chow or chow infused with the inducer doxycycline. Growth of Mtb was monitored by assessing CFU in lung tissue at day 30 post-infection. While there were no differences in the growth of wild type Mtb between treated and untreated mice, expression of the active site mutant significantly inhibited growth (Figure 5B). Our results suggest that functional ClpP1P2 protease is required for the growth of Mtb both in vitro and during infection.

Discussion

We find that the mycobacterial ClpP1P2 protease has two unusual properties that distinguishes it from other members of the
prokaryotic ClpP family. First, the protease consists of distinct types of subunits, each of which is required for full activity of a single proteolytic complex. While other species do encode multiple ClpP subunits, two different proteolytic subunits forming a single protease has not been documented. Second, unlike in most bacteria that have been studied, ClpP1P2 activity is absolutely required for normal growth. This requirement is particularly striking as mycobacteria contain several cytoplasmic ATP-dependent proteolytic complexes, including FtsH, and the proteasome [7, 25, 26]. Clearly, the mycobacterial ClpP1P2 proteolytic core has unique roles that are important for viability.

The ClpP proteases that have been characterized biochemically in other bacteria and mitochondria are tetracameric complexes containing a single type of proteolytic subunit. In mycobacteria, however, two different protein species contribute to protease activity. Although Mtb ClpP1 forms a tetracamer complex, a crystal structure of Mtb ClpP1 lacks appropriate active site geometry to support proteolysis [27]. The presence of two ClpP subunits with distinct substrate preferences may facilitate an expansion of the peptide specificity of the complex, much like the eukaryotic proteasome. Interestingly, the Mtb proteasome is composed of a single type of subunit, and the presence of distinct subunits comprising a single proteolytic core is rare among prokaryotes.

There is at least one example of an essential role for ClpP. In Caulobacter crescentus, ClpXP degrades CtrA, a protein that normally inhibits cell cycle progression during cellular replication [28]. In this case, a single protein target is responsible for the essentiality of the enzyme. ClpP1P2 protease might play a similar role in mycobacteria. While this may be true, screens for essential proteins in mycobacteria suggest that, in addition to the clpP1 and clpP2, multiple ClpP-associated ATPase adapters (clpX and clpC1) are also essential [18]. The requirement of multiple adapters makes it possible that accumulation of multiple protein substrates contribute to the poor growth phenotype observed on depleting the ClpP1 and ClpP2 subunits in mycobacteria.

ClpP1P2 might be important for other reasons. As shown here, ClpP1P2 protease is required for the clearance of SsrA-tagged proteins. These tagged polypeptides are generated under conditions when protein synthesis is stalled and are required for ribosome release. In the absence of ClpP1P2-mediated proteolysis, protein synthesis might eventually be inhibited. In addition, ClpP1P2 protease is necessary for degrading abnormal proteins, such as those produced in the presence of certain antibiotics. Accumulation of such non-functional misfolded proteins might result in cellular stress in the absence of an effective system for their removal [29]. Clearance of damaged proteins might be particularly important in Mtb during infection, when cells are exposed to multiple oxidative and nitrosative radicals that can induce protein damage. In fact, a transcriptional activator of the clpP1 operon, clgR, is critically activated upon reaeration of hypoxic Mtb and during Mtb growth within the macrophage [30, 31]. Degradation of pre-existing proteins during such stressful transitions may be the initial event that triggers adaptation and facilitates the bacterium’s ability to handle a wide array of environmental challenges. Using a dominant negative overexpression mutant in Mtb, we have confirmed that optimal ClpP proteolytic activity is required for growth during infection.

The essential nature of ClpP1P2 protease makes it an attractive target for antibiotic development, particularly because the proteases as a class are druggable enzymes and have already been validated as therapeutic targets in the treatment of HIV, hepatitis, and cancer [32]. In organisms where ClpP is not essential, uncontrolled activation of ClpP activity can be toxic. For example, in E. coli, acyldepsipeptide compounds reorganize the ClpP proteolytic core, causing dissociation from ATPase adapters, and indiscriminate protein degradation [33]. Compounds that produce a similar effect should result in toxicity in a broad range of
organisms. In fact, it was recently discovered that the natural product cyclomarin kills Mtb by targeting the ClpC1 ATPase and presumably increasing Clp-mediated proteolysis, as demonstrated in a whole cell fluorescence-based assay [34]. In mycobacteria, where ClpP1P2 protease activity is required and depletion of either subunit is bactericidal, either non-specific activation or inhibition could effectively limit bacterial growth. An example of a ClpP inhibitor with potential therapeutic activity already exists. In S. aureus, beta-lactones have been found to inhibit Clp protease activity and decrease the virulence of the organism [35]. Additionally, the synergistic nature of ClpP1P2 protease depletion with aminoglycosides, a class of drugs already used to treat tuberculosis, points to a potential combination therapy against Mtb. As ClpP1P2 protease is most likely involved in preventing the accumulation of misfolded proteins and the degradation of critical endogenous regulatory proteins, small molecule modulators of ClpP1P2 activity would target a critical aspect of Mtb physiology, and might prove useful in the face of growing multi-drug resistance in one of the world’s most successful pathogens.

**Materials and Methods**

**Ethics statement**

The animal experiments were performed with protocols approved by the Harvard Medical School Animal Management Program, which is accredited by the Association for Assessment...
and Accreditation of Laboratory Animal Care, International (AAALAC) and meets National Institute of Health standards as set forth in the Guide for the Care and Use of Laboratory Animals (Revised, 2010). The institution also accepts as mandatory the PHS Policy on Humane Care and Use of Laboratory Animals by Awardee Institutions and NIH Principles for the Utilization and Care of Vertebrate Animals Testing, Research, and Training. An Animal Welfare Assurance of Compliance is on file with the Office of Laboratory Animal Welfare (OLAW) (#A3431-01).

Bacterial strains and plasmids
Msm mc^2155 (Msm) or Mtb H37Rv were grown at 37°C in Middlebrook 7H9 broth with 0.05% Tween 80 and ADC (0.5% BSA, 0.2% dextrose, 0.085% NaCl, 0.003 g catalase/1L media). Mtb was additionally supplemented with oleic acid (0.006%). For growth curves, overnight cultures were diluted into the appropriate media and growth was either measured by OD 600 or colony forming units per mL. A summary of all strains, plasmids, and primers used in this study as well as a summary of the construction of conditional mutants can be found in the supporting information (Text S1).

Protein purification and in vitro peptidase assay
The C-terminally 6× His-tagged wild type clpP1, wild type clpP2, clpP1Ser^98Ala, and clpP2Ser^110Ala subunits were overexpressed in Msm using an anhydrotetracycline (ATc) inducible expression system. After overnight induction with ATc (100 ng/mL), cells were lysed by French press, and lysates were centrifuged for 1 h at 100,000 g. The subunits were purified from the supernatant by Ni-NTA affinity chromatography (Qiagen). Eluted fractions containing ClpP proteins were pooled and further purified by size exclusion chromatography on Sephacryl S-300 column. Equal amounts of ClpP1 and ClpP2 (1 µg each) were mixed in the reaction buffer (50 mM K-phosphate buffer pH 7,5, 100 mM KCl, 5% glycerol, 2 mM BME, 5 mM Z-Leu-Leu) and peptidase activity was measured by a rise in fluorescence at 460 nm (Ex at 340 nm) with 0.1 mM Z-Gly-Gly-Leu-AMC as a substrate. To measure dominant negative effect of active site mutants, same reaction was carried out in the presence of 5 µg of the mutant proteins.

Animal infections
Six to eight week old C57BL/6 mice (Jackson Laboratory) were used for animal infections. Mice were infected via aerosolization with 5×10^6 CFU each of a 3:1 mixture of Mtb pTet::ClpP1 S98A and Mtb pTet::GFP (wild type Mtb transformed with a control pTet plasmid containing GFP). Mice were fed with chow with or without inducer doxycycline. At 30 days after infection, mice were sacrificed, lungs were homogenized and appropriate dilutions were plated on 7H10 plates containing hygromycin or kanamycin to select for the Clp mutant or the control respectively.

Supporting Information
Figure S1 PCR confirmation of mycobacterial recombineering. Primers specific to the 5′-UTR and 3′-UTR of the clpP1P2 operon (RMR13 and RMR16, arrows) were used to distinguish wildtype Msm (expected fragment: 1.8 kb), Msm pTet::ClpP1 S98A and Msm pTet::GFP (wild type Mtb transformed with a control pTet plasmid containing GFP). Mice were fed with chow with or without inducer doxycycline. At 30 days after infection, mice were sacrificed, lungs were homogenized and appropriate dilutions were plated on 7H10 plates containing hygromycin or kanamycin to select for the Clp mutant or the control respectively. (TIF)

Figure S2 Increase in GFP-SsrA upon depletion of ClpP2 is not due to transcriptional activation of GFP-SsrA. Quantitative PCR of clpP2_ID was carried out to determine if
increase in GFP-SsrA was due to transcriptional activation. RNA was isolated from clpP2_ID four hours after induction with ATc (+ATc), and a culture of equal OD_{600} that was left uninduced (−ATc). Using both sigA (left) and 16s rRNA (right) as endogenous controls, there was no significant difference in transcription of GFP-SsrA between induced and uninduced cultures. Data are represented as mean fold change +/- standard deviation, with values normalized to those of the uninduced culture.

(Text S1 Supplementary methods.)

References

1. Ingmer H, Brøndsted L (2009) Proteases in bacterial pathogenesis. Res Microbiol 160: 704–710. doi:10.1016/j.resmic.2009.08.017.

2. Goldberg AL (2003) Protein degradation and protection against misfolded or damaged proteins. Nature 426: 893–899. doi:10.1038/nature02633.

3. Glickman MH, Ciechanover A (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82: 573–628. doi:10.1152/physrev.00027.2001.

4. Frees D, Savoji K, Varmaen P, Ingmer H (2007) Clp ATPases and ClpP proteolytic complexes regulate vital biological processes in low GC, Gram-positive bacteria. Mol Microbiol 63: 1285–1295. doi:10.1111/j.1365-2958.2007.05980.x.

5. Burns KE, Pearce MJ, Darwin KH (2010) Prokaryotic ubiquitin-like protein provides a two-part degrader to Mycobacterium protease substrates. J Bacteriol 192: 2933–2935. doi:10.1128/JB.01639-09.

6. Cerda-Maira FA, Pearce MJ, Fusettes M, Bishai WR, Hubbard SR, et al. (2010) Molecular analysis of the prokaryotic ubiquitin-like protein (Pup) conjugation pathway in Mycobacterium tuberculosis. Mol Microbiol 77: 1123–1135. doi:10.1111/j.1365-2958.2010.07276.x.

7. Darwin KH (2003) The Proteasome of Mycobacterium tuberculosis Is Required for Resistance to Nitric Oxide. Science 302: 534–538.

8. Smith CK, Baker TA, Sauer RT (1999) Lon and Clp family proteases and chaperones share homologous substrate-recognition domains. Proc Natl Acad Sci U S A 96: 6676–6682.

9. Kiran M, Chauhan A, Dredze R, Maloney E, Mukherji SK, et al. (2009) Mycobacterium tuberculosis fitsH expression in response to stress and viability. Tuberculosis (Edinb) 89: S70–S73. doi:10.1016/S1472-9792(09)70016-2.

10. Ingvarsen H, Mate M, Hoghoem M, Portnoi D, Benaroudj N, et al. (2007) Insights into the inter-ring plasticity of caseinolytic proteases from the X-ray structure of Mycobacterium tuberculosis ClpP1. Acta Crystallogr D Biol Crystallogr 63: 249–259. doi:10.1107/S0907444906055303.

11. Quon KC, Marczyński GT, Shapiro L (1996) Cell cycle control by an essential bacterial two-component signal transduction protein. Cell 84: 83–93.

12. Goldberg AL (1972) Degradation of abnormal proteins in Escherichia coli. J Struct Biol 43: 205–213. doi:10.1016/0022-510X(72)90015-7.

13. Boëttcher T, Sieber SA (2008) Beta-lactones as specific inhibitors of ClpP. Mol Microbiol 77: 5040–5043. doi:10.1111/j.1365-2958.2008.06045.x.

14. Prunteanu M, Baker TA (2009) Controlled degradation by ClpXP protease tunes nutrient response in Bacillus subtilis. Mol Microbiol 77: 3515–3524. doi:10.1111/j.1365-2958.2010.05598.x.

15. Estorninho M, Smith H, Thole J, Harders-Westerveen J, Kierzek A, et al. (2010) Insights into the inter-ring plasticity of caseinolytic proteases from the X-ray structure of Mycobacterium tuberculosis ClpP1. Acta Crystallogr D Biol Crystallogr 66: 249–259. doi:10.1107/S0907444910000530.

16. Wei J-R, Krishnamoorthy V, Murphy K, Kim J-H, Schnappinger D, et al. (2011) Depletion of antibiotic targets has widely varying effects on growth. Proc Natl Acad Sci USA 108: 19240–19245. doi:10.1073/pnas.1106311108.

17. Jenal U, Fuchs T (1998) An essential protease involved in bacterial cell-cycle control. EMBO J 17: 3560–3566. doi:10.1002/embo.171356609.

18. Sassetti CM, Boyd DH, Rubin EJ (2003) Genes required for induction of the mycobacterial recombineer- ing, Jun-Rong Wei for guidance on the inducible degradation system in mycobacteria, Noman Siddiqui for help with animal infections and the Taplin Mass Spectrometry Facility.

Author Contributions

Conceived and designed the experiments: RMR MU ALG EJR. Performed the experiments: RMR MU DHFR VK OK TNA. Analyzed the data: RMR MU EJR. Contributed reagents/materials/analysis tools: EJR ALG TNA OK. Wrote the paper: RMR MU EJR.

Acknowledgments

We thank Mike Chao for the plasmids that enabled this work, Chris Sassetti and Kenan Murphy for guidance on mycobacterial recombineering, Jun-Rong Wei for guidance on the inducible degradation system in mycobacteria, Noman Siddiqui for help with animal infections and the Taplin Mass Spectrometry Facility.

Importance of Clp Protease in Mycobacteria

PLoS Pathogens | www.plospathogens.org